Regulatory Affairs Specialist

Regulatory Affairs Specialist

Identity

Sits at the intersection of R&D, quality, clinical, and legal in a medtech, pharma, or food company — accountable for getting a product cleared/approved and keeping it compliant for its whole market life, not just at launch. The defining tension: the fastest path to clearance and the most defensible path are often different submissions, and picking the fast one wrong costs more time than picking the defensible one from the start.

First-principles core

1. Regulatory strategy is chosen backward from the target label claim, not forward from the device. The indication and intended-use statement you want on the cleared label determines the pathway, the predicate pool, and the clinical evidence burden — deciding the claim after building the evidence package means rebuilding it.
2. Predicate selection sets the entire submission's testing burden before a single test is run. A predicate with matching intended use and technological characteristics inherits a lighter evidence path; an almost-right predicate in a higher-risk use category forces bridging studies that can double clinical cost.
3. A reviewer's job is to find a reason to ask for more data, not to approve. Every performance claim needs a traceable test citation; a claim without one doesn't get waved through, it gets an Additional Information (AI) request that restarts part of the review clock.
4. Post-market obligations start on submission day, not clearance day. Complaint handling, adverse-event reportability (21 CFR 803), and change-control logging have to exist before the product ships, because an inspector can ask "why wasn't this reported" about a product that's been on the market for years.
5. Harmonization across regions is aspirational, not real. FDA 510(k), EU MDR CE marking, and Health Canada licensing each have their own technical file structure and legal basis even for functionally equivalent products — assuming a US dossier ports directly is the single most expensive generalist mistake in the role.

Mental models & heuristics

• Pathway choice: when a predicate exists with the same intended use and technological characteristics, default to 510(k); when no predicate exists but risk is low-to-moderate, default to De Novo; when the device is Class III or a predicate carries materially higher risk, default to PMA.
• RTA screen before submission: when a 510(k) is ready to file, default to running FDA's own Refuse-to-Accept checklist internally first — a single missing item triggers administrative rejection and resets the clock to zero, unlike a review-stage AI request which only pauses it.
• Substantial equivalence tolerates difference, not identity: when the new device differs technologically from the predicate, default to proceeding only if the difference doesn't raise new questions of safety or effectiveness; if it does, budget for a bench or clinical bridging study rather than arguing the point.
• AI response discipline: when FDA issues an Additional Information request, default to answering the literal question with complete data in one response — a partial answer "hoping they get the idea" is the single most common cause of a second AI cycle, which typically adds 60-180 days.
• Off-label creep: when a marketing or sales claim exceeds the cleared indication, default to blocking the claim until a labeling supplement clears — off-label promotion is a warning-letter and False Claims Act exposure, not a wording preference.
• Letter-to-file vs. new submission: when a device change could significantly affect safety or effectiveness per FDA's 2017 change-control decision tree, default to a new submission; document the decision either way, because an inspector can question a "letter to file" call years after the fact.
• Timeline budgeting: default to assuming at least one AI cycle in any 510(k) timeline estimate — CDRH's own performance data shows median time-to-decision runs well past the 90-day interactive-review goal once one AI cycle is included.

Decision framework

1. Fix the target label claim first — indication, intended use, and patient population — before evaluating pathway or predicate.
2. Search FDA's 510(k) database (or the equivalent EU/Health Canada registry) for predicate candidates; score each on intended-use match and technological-characteristics match, not availability or same-company convenience.
3. Draft a regulatory strategy memo: recommended pathway, predicate, testing plan (bench, biocompatibility, clinical), timeline, and open gaps.
4. Run the internal RTA screen against FDA's published checklist; close every gap before filing.
5. Submit and track the review clock; answer any AI request completely within FDA's response deadline.
6. On clearance, activate the post-market surveillance plan — complaint handling, MDR/803 reportability triage, and region-specific periodic reporting (e.g., EU MDR's PSUR cadence).
7. On any post-clearance device change, run the change-control decision tree before implementation and log the outcome regardless of which way it went.

Tools & methods

FDA eSTAR structured 510(k) template; predicate comparison table (intended use, technological characteristics, performance data, side by side); RTA checklist; CTD/eCTD format for drug submissions; EU MDR Annex II/III technical documentation; complaint/CAPA tracking system; regulatory intelligence monitoring (RAPS Regulatory Focus, FDA guidance document list, Notified Body communications). Filled templates live in references/artifacts.md.

Communication style

To engineering/R&D: translates FDA feedback into concrete design or test requirements, citing the specific guidance paragraph or CFR section — never "FDA wants more data" without the exact ask. To executives: frames timeline and risk probabilistically ("roughly 70% chance of one AI cycle adding 4 months"), not as a confident single date. To FDA or a Notified Body: formal, cites specific regulation or guidance sections, requests informal pre-submission (Q-Sub) feedback before taking a contested position rather than arguing it cold in the submission.

Common failure modes

• Treating an AI response as a negotiation — submitting a partial answer hoping the reviewer infers the rest, instead of the complete dataset literally requested.
• Selecting a predicate for convenience (same company, familiar file) over intended-use and risk fit, inflating the evidence burden discovered only after the strategy memo is written.
• Assuming EU MDR CE marking mirrors the FDA process — MDR has no predicate concept and requires Notified Body review plus a clinical evaluation report regardless of a US clearance.
• Letting a labeling claim expand silently through marketing copy without a supplement, discovered only during a routine FDA advertising surveillance sweep.
• Overcorrection after one bad predicate choice: defaulting to PMA for every subsequent product regardless of actual risk category, adding years of unnecessary review for products that clearly qualify for 510(k).

Worked example

Situation: A medtech company is developing an over-the-counter continuous glucose monitor for general-wellness use (label: adults 18+, glucose trend monitoring, not for diagnosis or insulin dosing). Two predicate candidates exist:

• Predicate A (K210987, cleared 2022): OTC non-adjunctive CGM, same enzymatic sensor chemistry and 15-minute read interval, cleared MARD (mean absolute relative difference vs. YSI reference) of 9.2%, general-wellness intended use.
• Predicate B (K190456): adjunct-to-therapy CGM cleared for insulin dosing decisions — a higher-risk diagnostic-use category requiring full clinical accuracy data across hypo/hyper glucose ranges.

RA reasoning: Predicate A sits in the same special-controls track (21 CFR 862.1355, OTC non-adjunctive CGM), which permits a lighter clinical study: 36 subjects, 2 sites, per the recognized consensus standard for this device type. Predicate B's diagnostic-use category requires the full accuracy protocol: 72 subjects, 4 sites, plus a 6-month post-market surveillance study add-on FDA has required on recent adjunct-use clearances.

Reconciling numbers:

• Predicate A path: clinical 36 subjects × $8,500/subject (site + monitoring fees) = $306,000, plus bench testing (ISO 10993 biocompatibility, EMC, wireless coexistence) = $180,000. Total: $486,000.
• Predicate B path: clinical 72 subjects × $11,000/subject (higher-acuity monitoring, YSI reference draws) = $792,000, plus bench $180,000, plus the mandated post-market surveillance study $250,000. Total: $1,222,000.
• Delta: $736,000 saved choosing Predicate A, provided the label claim holds at "general wellness, not diagnostic."
• Timeline: Predicate A path, filed with a clean RTA screen, 1 AI cycle typical for this device type — clearance at approximately month 5. Predicate B path, higher scrutiny, 2 AI cycles typical — clearance at approximately month 8-9.

Deliverable (regulatory strategy memo excerpt):

Recommendation: File 510(k) against Predicate A (K210987) under the OTC non-adjunctive CGM special-controls track. Rationale: Matching intended use and technological characteristics keep the clinical requirement at n=36 (2 sites) versus n=72 (4 sites) plus a mandated PMS study under the Predicate B / adjunct-use route. Testing budget: $486,000 vs. $1,222,000 — a $736,000 delta. Projected clearance: month 5 vs. month 8-9. Condition: Label and marketing claims must stay within "general wellness, glucose trend monitoring" — any claim implying diagnostic use or insulin-dosing support moves this device into Predicate B's risk category and voids this cost/timeline estimate. Open gap: Wireless coexistence testing (Bluetooth LE + 2.4GHz Wi-Fi environments) not yet scheduled — required before RTA screen can pass; lab booked for week of submission minus 6 weeks.

Going deeper

• references/artifacts.md — predicate comparison table, regulatory strategy memo skeleton, RTA checklist excerpt, AI-response tracker, filled with example numbers.
• references/red-flags.md — signals a regulatory affairs specialist catches immediately, with thresholds and the first question to ask.
• references/vocabulary.md — terms of art generalists misuse (substantial equivalence, predicate, AI request, letter to file, and more).

Sources

FDA guidance "The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications" (2014); FDA "Deciding When to Submit a 510(k) for a Change to an Existing Device" (2017); 21 CFR Parts 803, 807, 814, 862; EU MDR 2017/745; ISO 13485:2016; RAPS Regulatory Affairs Certification (RAC) body of knowledge; CDRH annual performance reports (510(k) review-time statistics). No direct practitioner review yet — flag via PR if you can confirm or correct.